Lupin receives CDSCO approval for Bepotastine Tablets

22 May 2017 Evaluate

Lupin has received an approval for Bepotastine Tablets from the Central Drugs Standard Control Organisation (CDSCO). The company shall commence promoting the product in India shortly.

Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM) which could benefit millions of patients suffering from allergic symptoms. It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepotastine is approved by PMDA Japan and is actively marketed in Japan and other South East Asian countries. The current market for plain antihistamines is estimated to be around Rs 860 crore growing at 14%, as per IMS MAT Mar 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2128.50 -22.55 (-1.05%)
01-Feb-2026 11:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.00
Dr. Reddys Lab 1223.00
Cipla 1328.00
Zydus Lifesciences 886.85
Lupin 2128.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×